{"id":"dapt","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"Baxter Hlthcare Corp","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Abnormal liver function tests","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated creatine phosphokinase (CPK)","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary tract infections","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Sepsis","drugRate":"","severity":"common","organSystem":""},{"effect":"Bacteremia","drugRate":"","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Edema","drugRate":"","severity":"common","organSystem":""},{"effect":"Pharyngolaryngeal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased sweating","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Diarrhea","Disorder of muscle","Eosinophilic asthma","Increased Creatine Phosphokinase","Neuropathy","Pseudomembranous enterocolitis"],"seriousAdverseEvents":[{"effect":"Anaphylaxis/Hypersensitivity Reactions","drugRate":"","severity":"serious"},{"effect":"Myopathy and Rhabdomyolysis","drugRate":"","severity":"serious"},{"effect":"Eosinophilic Pneumonia","drugRate":"","severity":"serious"},{"effect":"Drug Reaction with Eosinophilia and Systemic Symptoms","drugRate":"","severity":"serious"},{"effect":"Tubulointerstitial Nephritis","drugRate":"","severity":"serious"},{"effect":"Peripheral Neuropathy","drugRate":"","severity":"serious"},{"effect":"Increased International Normalized Ratio (INR)/Prolonged Prothrombin Time","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Active comparator","Dual antiplatelet therapy","Dual Anti Platelet Therapy","Ticagrelor or clopidogrel + aspirin","dual antiplatelet therapy"],"company":"Baxter Hlthcare Corp","patents":[{"applNo":"N213645","source":"FDA Orange Book","status":"Active","expires":"Mar 11, 2041","useCode":"U-3294","territory":"US","drugProduct":true,"patentNumber":"11173189","drugSubstance":false}],"pricing":[],"allNames":["dapt"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Assistance Publique - Hôpitaux de Paris to Baxter Hlthcare Corp"},{"date":"2016-07-06","type":"positive","source":"FDA Orange Book","milestone":"Cubicin Rf approved — 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2017-09-12","type":"positive","source":"FDA Orange Book","milestone":"Daptomycin approved — 350MG/VIAL"},{"date":"2017-10-20","type":"positive","source":"FDA Orange Book","milestone":"Daptomycin approved — 350MG/VIAL"},{"date":"2018-04-11","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"},{"date":"2021-06-21","type":"positive","source":"FDA Orange Book","milestone":"Daptomycin approved — 350MG/VIAL"},{"date":"2023-01-30","type":"positive","source":"FDA Orange Book","milestone":"Daptomycin approved — 350MG/VIAL"},{"date":"2024-11-21","type":"positive","source":"FDA Orange Book","milestone":"Daptomycin approved — 350MG/VIAL"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Outer membrane porin protein OmpD","modality":"Small Molecule","explanation":"Imagine your body's cells are like locks, and Dapt is a key that fits into those locks. When Dapt binds to its target, it can either block or enhance the activity of that target, depending on the specific lock it's interacting with. This can help to either reduce or increase the activity of certain cellular processes, but the exact way it works is still a mystery.","oneSentence":"Dapt is a small molecule that works by interacting with specific biological targets, but the exact details of this interaction are unknown.","technicalDetail":"As a small molecule, Dapt is likely to work through a specific binding interaction with its target, potentially altering the activity of a particular enzyme, receptor, or other protein. The exact nature of this interaction is unknown, but it may involve hydrogen bonding, ionic interactions, or other types of non-covalent binding."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=dapt","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=dapt","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:31:17.164619","biosimilars":[],"competitors":[],"genericName":"dapt","indications":{"approved":[{"name":"Bacteremia caused by Staphylococcus aureus","diseaseId":"bacteremia-caused-by-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Skin and Skin Structure Enterococcus Faecalis Infection","diseaseId":"complicated-skin-and-skin-structure-enterococcus-faecalis-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","diseaseId":"complicated-skin-and-skin-structure-staphylococcus-aureus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Skin and Skin Structure Streptococcus Agalactiae Infection","diseaseId":"complicated-skin-and-skin-structure-streptococcus-agalactiae-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Skin and Skin Structure Streptococcus Pyogenes Infection","diseaseId":"complicated-skin-and-skin-structure-streptococcus-pyogenes-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Skin and Skin Structure Streptococcus dysgalactiae Infection","diseaseId":"complicated-skin-and-skin-structure-streptococcus-dysgalactiae-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Right-sided Staphylococcus aureus endocarditis","diseaseId":"right-sided-staphylococcus-aureus-endocarditis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Secondary infection of erosion and ulcer caused by MRSA","diseaseId":"secondary-infection-of-erosion-and-ulcer-caused-by-mrsa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Secondary infection of surgical wounds caused by MRSA","diseaseId":"secondary-infection-of-surgical-wounds-caused-by-mrsa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Secondary infection of trauma, and burn wounds caused by MRSA","diseaseId":"secondary-infection-of-trauma-and-burn-wounds-caused-by-mrsa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis caused by methicillin resistant Staphylococcus aureus","diseaseId":"sepsis-caused-by-methicillin-resistant-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis due to Staphylococcus aureus","diseaseId":"sepsis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Baxter Hlthcare Corp","drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":["Coronary Artery Disease"],"enrollment":3944,"completionDate":"2028-12-31"},{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":["Acute Coronary Syndrome"],"enrollment":14194,"completionDate":"2026-02-06"},{"nctId":"NCT04276155","phase":"PHASE4","title":"Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier de PAU","startDate":"2021-08-03","conditions":["Atrial Fibrillation, Myocardial Infarction"],"enrollment":500,"completionDate":"2027-06-22"},{"nctId":"NCT07480629","phase":"","title":"The 10-Year Extended Follow-up of the DACAB Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2026-03-15","conditions":["Coronary Artery Disease","CABG","Antiplatelet Therapy of Coronary Artery Bypass"],"enrollment":500,"completionDate":"2026-06"},{"nctId":"NCT06521463","phase":"NA","title":"SIMPLAAFY Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-10-01","conditions":["Atrial Fibrillation","Stroke","Bleeding"],"enrollment":1857,"completionDate":"2027-01"},{"nctId":"NCT05702034","phase":"PHASE3","title":"A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-15","conditions":["Ischemic Stroke; Ischemic Attack, Transient"],"enrollment":15000,"completionDate":"2026-12-09"},{"nctId":"NCT07471867","phase":"PHASE4","title":"Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-03-17","conditions":["Chronic Coronary Syndrome"],"enrollment":100,"completionDate":"2028-07-12"},{"nctId":"NCT07257198","phase":"PHASE3","title":"Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","status":"RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-03-03","conditions":["NSTEMI - Non-ST Segment Elevation MI","STEMI (ST Elevation MI)","Myocardial Infarction"],"enrollment":2570,"completionDate":"2031-01-01"},{"nctId":"NCT07007143","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-07-31","conditions":["Mitral Regurgitation"],"enrollment":1032,"completionDate":"2029-09-30"},{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":["Coronary Artery Disease"],"enrollment":90,"completionDate":"2027-03-31"},{"nctId":"NCT06916520","phase":"PHASE4","title":"Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)","status":"RECRUITING","sponsor":"J.P.S Henriques","startDate":"2025-11-13","conditions":["Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)"],"enrollment":300,"completionDate":"2027-04"},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":["Coronary Arterial Disease (CAD)"],"enrollment":90,"completionDate":"2027-02-28"},{"nctId":"NCT03981835","phase":"","title":"Management of Antiplatelet Regimen During Surgical Procedures","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2019-08-01","conditions":["Cardiac Surgery","Surgery","Percutaneous Coronary Intervention","Surgery--Complications"],"enrollment":147,"completionDate":"2024-01-30"},{"nctId":"NCT06691191","phase":"PHASE4","title":"Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-01-08","conditions":["Coronary Artery Disease"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT07391358","phase":"NA","title":"DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid","status":"NOT_YET_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-02-01","conditions":["Acute Coronary Syndrome"],"enrollment":26,"completionDate":"2026-12-31"},{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":["Stroke, Acute","Stroke, Ischemic","Cerebral Infarction"],"enrollment":458,"completionDate":"2029-05-01"},{"nctId":"NCT07111559","phase":"PHASE4","title":"Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","status":"RECRUITING","sponsor":"Nippon Medical School","startDate":"2025-08-01","conditions":["Lacunar Stroke","Stroke","Ischemic Stroke"],"enrollment":500,"completionDate":"2029-03-31"},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":["ST Elevation Myocardial Infarction"],"enrollment":350,"completionDate":"2028-03-01"},{"nctId":"NCT07374718","phase":"NA","title":"Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2026-03-01","conditions":["Acute Coronary Syndrome (ACS)","High Bleeding Risk(HBR)","Coronary Artery Disease (CAD)"],"enrollment":468,"completionDate":"2029-06-30"},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":["Coronary Disease","Heart Diseases","Cardiovascular Diseases","Myocardial Ischemia","Atherosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Coronary Artery Disease","Acute Coronary Syndrome","Coronary Stenosis","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel"],"enrollment":576,"completionDate":"2028-02-20"},{"nctId":"NCT07354828","phase":"","title":"Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2025-12-30","conditions":["Acute Coronary Syndrome (ACS)","High Bleeding Risk (HBR)","Coronary Artery Disease (CAD)"],"enrollment":3500,"completionDate":"2029-06-30"},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":["Heart Failure With Reduced Ejection Fraction","Coronary Artery Disease"],"enrollment":654,"completionDate":"2028-01-30"},{"nctId":"NCT07032389","phase":"PHASE2","title":"A Polypill for Acute Coronary Syndrome","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-12-05","conditions":["Acute Coronary Syndrome"],"enrollment":1000,"completionDate":"2029-08-01"},{"nctId":"NCT05577988","phase":"PHASE3","title":"Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-18","conditions":["MYOCARDIAL INFARCTION"],"enrollment":2468,"completionDate":"2027-06"},{"nctId":"NCT07076082","phase":"PHASE4","title":"Vascular Trial Associated Registry Pilot","status":"RECRUITING","sponsor":"Corewell Health West","startDate":"2025-10-15","conditions":["Peripheral Arterial Disease"],"enrollment":350,"completionDate":"2028-10-30"},{"nctId":"NCT07195149","phase":"PHASE3","title":"Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)","status":"RECRUITING","sponsor":"Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.","startDate":"2025-11-25","conditions":["Chronic Coronary Syndrome","Stable Coronary Artery Disease CAD"],"enrollment":1703,"completionDate":"2030-11-30"},{"nctId":"NCT07299994","phase":"","title":"Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","status":"NOT_YET_RECRUITING","sponsor":"Sigmund Freud PrivatUniversitat","startDate":"2026-01-01","conditions":["Stroke","Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","Acute Ischemic Stroke"],"enrollment":462,"completionDate":"2026-04-30"},{"nctId":"NCT05997693","phase":"PHASE3","title":"One-Month DAPT in CABG Patients","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-08-15","conditions":["Chronic Coronary Disease"],"enrollment":700,"completionDate":"2031-01"},{"nctId":"NCT04783701","phase":"","title":"Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)","status":"RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2021-05-17","conditions":["Acute Coronary Syndrome","Coronary Bypass Stenosis"],"enrollment":360,"completionDate":"2026-03-15"},{"nctId":"NCT06321757","phase":"","title":"PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients","status":"RECRUITING","sponsor":"Fundación EPIC","startDate":"2024-02-26","conditions":["Coronary Artery Disease"],"enrollment":501,"completionDate":"2026-12-30"},{"nctId":"NCT07198529","phase":"NA","title":"OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","status":"RECRUITING","sponsor":"Korea University Guro Hospital","startDate":"2025-09-30","conditions":["Stable Angina","Coronary Artery Disease"],"enrollment":130,"completionDate":"2029-09"},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":["Left Main Coronary Artery Stenosis"],"enrollment":828,"completionDate":"2031-05-01"},{"nctId":"NCT04624854","phase":"PHASE4","title":"Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)","status":"COMPLETED","sponsor":"Harbin Medical University","startDate":"2020-10-28","conditions":["Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Heart Diseases","Syndrome Heart Disease","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Coronary Disease","Vascular Diseases"],"enrollment":8250,"completionDate":"2025-09-23"},{"nctId":"NCT06742931","phase":"NA","title":"Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-04-07","conditions":["Chronic Coronary Syndrome"],"enrollment":1200,"completionDate":"2031-12-31"},{"nctId":"NCT07039149","phase":"","title":"Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents","status":"RECRUITING","sponsor":"Jordan Collaborating Cardiology Group","startDate":"2025-08-01","conditions":["Major Bleeding","Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)"],"enrollment":200,"completionDate":"2026-11-01"},{"nctId":"NCT06857045","phase":"NA","title":"Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation","status":"WITHDRAWN","sponsor":"Sino Medical Sciences Technology Inc.","startDate":"2024-07-09","conditions":["Intracranial Arteriosclerosis","Intracranial Artery Stenosis","Drug-Eluting Stents"],"enrollment":0,"completionDate":"2026-06"},{"nctId":"NCT07238764","phase":"NA","title":"OCT-based DAPT Cessation in HBR Patients","status":"COMPLETED","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2022-06-12","conditions":["High Bleeding Risk Patients","DAPT(Dual Antiplatelet Therapy)","Coronary Artery Disease","Diabetes Mellitus"],"enrollment":40,"completionDate":"2025-05-09"},{"nctId":"NCT05782270","phase":"PHASE4","title":"Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-04-11","conditions":["Anticoagulation","Coronary Endarterectomy"],"enrollment":202,"completionDate":"2026-05-30"},{"nctId":"NCT07025148","phase":"PHASE4","title":"Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-10-01","conditions":["Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)"],"enrollment":40,"completionDate":"2027-11-01"},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":["Acute Myocardial Infarction"],"enrollment":2312,"completionDate":"2028-01-31"},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":["Coronary Artery Disease (CAD)","Percutaneous Coronary Intervention (PCI)","Antiplatelet Therapy","Elderly (People Aged 65 or More)"],"enrollment":1700,"completionDate":"2029-10"},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":["ST Elevation Myocardial Infarction","No-Reflow Phenomenon"],"enrollment":60,"completionDate":"2028-05"},{"nctId":"NCT06665919","phase":"NA","title":"The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models","status":"COMPLETED","sponsor":"Vistamedi Ltd.","startDate":"2023-06-15","conditions":["Coronary Artery Disease","Clopidogrel Resistance","Coronary Thrombosis","Adverse Cardiac Events","Bleeding","Hospitalisations","Death","Death From Cardiovascular Disease"],"enrollment":283,"completionDate":"2025-07-05"},{"nctId":"NCT04728516","phase":"PHASE4","title":"The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-12","conditions":["Acute Coronary Syndrome","Helicobacter Pylori Infection"],"enrollment":2600,"completionDate":"2026-06-30"},{"nctId":"NCT05732701","phase":"NA","title":"Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-27","conditions":["Percutaneous Coronary Intervention","Platelet Aggregation Inhibitors","Coronary Artery Disease"],"enrollment":2788,"completionDate":"2028-12"},{"nctId":"NCT07169513","phase":"NA","title":"Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-10-01","conditions":["Peripheral Arterial Disease","Silent Atherosclerosis"],"enrollment":60,"completionDate":"2026-07-01"},{"nctId":"NCT06216821","phase":"NA","title":"OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time","status":"RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2024-07-02","conditions":["Acute Coronary Syndrome"],"enrollment":3490,"completionDate":"2027-12-31"},{"nctId":"NCT05380063","phase":"PHASE4","title":"Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting","status":"COMPLETED","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-02-14","conditions":["Coronary Artery Disease","Coronary Artery Bypass Grafting","Dual Antiplatelet Therapy","Bleeding","Myocardial Infarction","Myocardial Ischemia","Angina Pectoris"],"enrollment":2300,"completionDate":"2025-07-10"},{"nctId":"NCT03431142","phase":"PHASE4","title":"Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2018-02-12","conditions":["Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage"],"enrollment":7758,"completionDate":"2020-12-30"},{"nctId":"NCT07125651","phase":"","title":"Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09-01","conditions":["Gastro Intestinal Bleeding","Ischaemic Heart Diseases","Antiplatelet Drugs","Antiplatelet Drug-related Gastrointestinal Injury"],"enrollment":112,"completionDate":"2026-10"},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":["In-stent Restenosis"],"enrollment":252,"completionDate":"2027-10-29"},{"nctId":"NCT05491200","phase":"PHASE4","title":"Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients","status":"RECRUITING","sponsor":"Research Maatschap Cardiologen Rotterdam Zuid","startDate":"2022-07-22","conditions":["ST Elevated Myocardial Infarction","Dual Antiplatelet Therapy"],"enrollment":1656,"completionDate":"2028-08-01"},{"nctId":"NCT04753749","phase":"NA","title":"Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy","status":"COMPLETED","sponsor":"MicroPort CRM","startDate":"2021-03-25","conditions":["Myocardial Infarction, Acute","Coronary Artery Disease"],"enrollment":2248,"completionDate":"2025-05-05"},{"nctId":"NCT05631769","phase":"PHASE4","title":"HOST - DAPT Duration According the Bleeding Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-07-24","conditions":["Coronary Artery Disease","Acute Myocardial Infarction","Stable Angina"],"enrollment":4900,"completionDate":"2027-12-31"},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":["Chronic Coronary Syndrome"],"enrollment":1000,"completionDate":"2027-09"},{"nctId":"NCT06981390","phase":"NA","title":"Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG","status":"RECRUITING","sponsor":"Kexiang Liu, MD","startDate":"2025-02-01","conditions":["Coronary Artery Disease","Coronary Artery Bypass Grafting","Saphenous Vein","Dual Antiplatelet Therapy"],"enrollment":300,"completionDate":"2026-03-20"},{"nctId":"NCT06276374","phase":"NA","title":"Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients","status":"RECRUITING","sponsor":"Woo-Keun Seo","startDate":"2024-07-15","conditions":["Carotid Artery Diseases"],"enrollment":1556,"completionDate":"2030-12-31"},{"nctId":"NCT06014060","phase":"NA","title":"24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-06-20","conditions":["Elevated Lipoprotein(a) Level","Coronary Artery Disease","Drug-Eluting Stent","Dual Antiplatelet Therapy"],"enrollment":3300,"completionDate":"2028-12-31"},{"nctId":"NCT07068490","phase":"","title":"Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-10-22","conditions":["Coronary Artery Disease"],"enrollment":100000,"completionDate":"2025-12-31"},{"nctId":"NCT06564909","phase":"PHASE2","title":"Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-01","conditions":["Reperfusion Injury, Myocardial","Myocardial Infarction"],"enrollment":76,"completionDate":"2026-03"},{"nctId":"NCT03971500","phase":"NA","title":"1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-08-20","conditions":["Coronary Artery Disease"],"enrollment":3710,"completionDate":"2025-12-30"},{"nctId":"NCT07024446","phase":"","title":"Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-07-01","conditions":["PCI Patients","DAPT(Dual Antiplatelet Therapy)","Hip Fracture Surgeries"],"enrollment":50,"completionDate":"2027-07-01"},{"nctId":"NCT04870047","phase":"NA","title":"Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Phenox GmbH","startDate":"2021-09-03","conditions":["Intracranial Aneurysm"],"enrollment":171,"completionDate":"2025-12"},{"nctId":"NCT07000617","phase":"PHASE2","title":"A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-03-21","conditions":["NK/T Cell Lymphoma"],"enrollment":57,"completionDate":"2028-12"},{"nctId":"NCT05305482","phase":"NA","title":"DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-08-10","conditions":["Acute Coronary Syndrome"],"enrollment":3520,"completionDate":"2030-02-14"},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":["Coronary Artery Disease"],"enrollment":100,"completionDate":"2024-03-22"},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":["Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","High Bleeding Risk"],"enrollment":3000,"completionDate":"2029-12-31"},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":["Coronary Artery Disease"],"enrollment":2312,"completionDate":"2030-08"},{"nctId":"NCT05566301","phase":"","title":"Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)","status":"RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2021-09-02","conditions":["Clopidogrel, Poor Metabolism of","Carotid Stenosis"],"enrollment":1140,"completionDate":"2026-12-31"},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":["Stroke","Transient Ischemic Attack (TIA)"],"enrollment":200,"completionDate":"2029-04-01"},{"nctId":"NCT06821191","phase":"PHASE4","title":"Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-03-10","conditions":["Coronary Artery Disease"],"enrollment":78,"completionDate":"2027-01-07"},{"nctId":"NCT06899399","phase":"NA","title":"Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-10-18","conditions":["Asymptomatic Carotid Artery Stenosis"],"enrollment":982,"completionDate":"2028-07"},{"nctId":"NCT05329155","phase":"NA","title":"Early Administration of Heparin At FMC for PPCI of STEMI Patients","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2022-07-20","conditions":["STEMI","Primary PCI"],"enrollment":1145,"completionDate":"2024-08-20"},{"nctId":"NCT06736626","phase":"","title":"The xDAPT External Validation Study","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-01-01","conditions":["Coronary Artery Disease","Percutaneous Coronary Intervention"],"enrollment":30000,"completionDate":"2024-12-01"},{"nctId":"NCT03447379","phase":"NA","title":"Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2017-12-15","conditions":["Coronary Artery Disease"],"enrollment":1452,"completionDate":"2022-08-17"},{"nctId":"NCT06871358","phase":"NA","title":"The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2024-09-01","conditions":["STEMI (STE-ACS)","Primary PCI for STEMI"],"enrollment":40,"completionDate":"2024-11-20"},{"nctId":"NCT06718179","phase":"PHASE4","title":"Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":["Acute Coronary Syndrome"],"enrollment":3150,"completionDate":"2030-12"},{"nctId":"NCT06075420","phase":"","title":"Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2021-08-18","conditions":["Percutaneous Coronary Intervention","Dual Antiplatelet Therapy"],"enrollment":1000,"completionDate":"2027-12-31"},{"nctId":"NCT06075433","phase":"","title":"Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2022-05-13","conditions":["Coronary Artery Disease","Percutaneous Coronary Intervention","Dual Antiplatelet Therapy"],"enrollment":1000,"completionDate":"2027-12-31"},{"nctId":"NCT03805048","phase":"NA","title":"PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2019-01-22","conditions":["Coronary Artery Disease"],"enrollment":221,"completionDate":"2028-06-30"},{"nctId":"NCT04418479","phase":"PHASE4","title":"SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3","status":"COMPLETED","sponsor":"Joo-Yong Hahn","startDate":"2020-08-10","conditions":["Coronary Artery Disease"],"enrollment":5506,"completionDate":"2024-11-12"},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":["Coronary Artery Disease","Atherosclerosis","Stent Placement"],"enrollment":50,"completionDate":"2022-08-08"},{"nctId":"NCT06742567","phase":"PHASE3","title":"Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","status":"RECRUITING","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-12-02","conditions":["Acute Myocardial Infarction of Anterior Wall","Left Ventricular Thrombus","Prophylaxis"],"enrollment":472,"completionDate":"2025-11-30"},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":["Coronary Artery Disease","Myocardial Infarction"],"enrollment":390,"completionDate":"2026-09"},{"nctId":"NCT05476081","phase":"","title":"A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2021-02-03","conditions":["Ischemic Stroke","TIA"],"enrollment":2239,"completionDate":"2023-05-03"},{"nctId":"NCT05071027","phase":"NA","title":"Dual Antiplatelet Therapy Adherence With Reminder App Usage","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-10-27","conditions":["Aneurysm Cerebral (Unruptured)"],"enrollment":9,"completionDate":"2024-07-22"},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":["Vertebral Artery Stenosis"],"enrollment":520,"completionDate":"2026-12"},{"nctId":"NCT05360602","phase":"NA","title":"Alpha Lipoic Acid Effect on No-Reflow Phenomenon","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":["No-Reflow Phenomenon"],"enrollment":70,"completionDate":"2024-01-31"},{"nctId":"NCT05320926","phase":"NA","title":"Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-07-26","conditions":["Ischemic Heart Disease"],"enrollment":3744,"completionDate":"2028-07-10"},{"nctId":"NCT06648720","phase":"NA","title":"Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Ho Chi Minh City (UMC)","startDate":"2025-03-01","conditions":["Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)","Intravascular Ultrasound","Dual Antiplatelet Therapy"],"enrollment":3566,"completionDate":"2029-03-01"},{"nctId":"NCT06577896","phase":"","title":"The Study to Evaluate the Safety and Efficacy of the Onyx Family","status":"RECRUITING","sponsor":"Pusan National University Yangsan Hospital","startDate":"2022-06-09","conditions":["Coronary Artery Disease"],"enrollment":500,"completionDate":"2026-12-31"},{"nctId":"NCT04937699","phase":"PHASE4","title":"Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-28","conditions":["Acute Coronary Syndrome","Percutaneous Coronary Intervention"],"enrollment":2690,"completionDate":"2026-12-31"},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":["Myocardial Infarction With Non-Obstructive Coronary Arteries"],"enrollment":120,"completionDate":"2025-07"},{"nctId":"NCT05077683","phase":"PHASE3","title":"Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-10","conditions":["Myocardial Infarction, Acute","Left Ventricular Thrombus"],"enrollment":560,"completionDate":"2024-02-09"},{"nctId":"NCT03419325","phase":"EARLY_PHASE1","title":"A Genomic Approach for Clopidogrel in Caribbean Hispanics","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Puerto Rico","startDate":"2020-09-01","conditions":["Cardiovascular Disease (CVD)","Stroke","Acute Coronary Syndrome","Peripheral Arterial Disease","Coronary Artery Disease","Myocardial Infarction"],"enrollment":150,"completionDate":"2024-12-30"},{"nctId":"NCT02939872","phase":"PHASE4","title":"Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2017-03-09","conditions":["Percutaneous Transluminal Coronary Angioplasty","Coronary Disease"],"enrollment":238,"completionDate":"2024-06-03"},{"nctId":"NCT05660811","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-09-28","conditions":["Atrial Fibrillation"],"enrollment":80,"completionDate":"2026-06"},{"nctId":"NCT04240834","phase":"PHASE4","title":"Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2021-02-01","conditions":["Acute Coronary Syndrome","Interventional Cardiology"],"enrollment":1220,"completionDate":"2026-12"},{"nctId":"NCT02619760","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2015-12","conditions":["Coronary Artery Disease"],"enrollment":3045,"completionDate":"2023-12-31"},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":["Acute Coronary Syndrome"],"enrollment":6002,"completionDate":"2025-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Assistance Publique - Hôpitaux de Paris","relationship":"Original Developer"},{"period":"present","companyName":"Baxter Hlthcare Corp","relationship":"Current Owner"}],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"Assistance Publique - Hôpitaux de Paris","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":19,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Aspiro","Be Pharms","Biocon Pharma","Dr Reddys","Eugia Pharma","Fresenius Kabi Usa","Hainan Poly Pharm","Hangzhou Zhongmei","Hengrui Pharma","Hisun Pharm Hangzhou","Hospira","Meitheal","Mylan","Mylan Labs Ltd","Qilu Pharm Hainan","Sagent Pharms Inc","Teva Pharms Usa","Xellia Pharms Aps"],"status":"active","brandName":"DAPT","companyName":"Baxter Hlthcare Corp","companyId":"baxter","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapt is a small molecule drug developed by Assistance Publique - Hôpitaux de Paris and currently owned by Baxter Healthcare Corp. However, due to the lack of information on its target, drug class, and approved indications, its exact mechanism and clinical use are unclear. As a small molecule, it is likely to work by interacting with specific biological targets, but the details of this interaction are unknown. Dapt is available as a generic medication, with 19 generic manufacturers, but its commercial status and safety considerations are not well-documented. Further research is needed to fully understand this medication.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":24,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}